Literature DB >> 8859080

Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat.

C K Dorey1, S Aouididi, X Reynaud, H F Dvorak, L F Brown.   

Abstract

OBJECTIVE: To determine whether neovascularization was spatially correlated with the distribution of messenger RNA for vascular permeability factor/vascular endothelial growth factor (VPF/VEGF).
METHODS: Neonatal rats were raised 8 days in 80% oxygen with daily intervals of relative hypoxia in room air, then transferred to room air for 5, 7, or 10 additional days. In situ hybridization for VPF/VEGF expression and avascular area were examined in retinas from oxygen-exposed animals and room-air controls. Severity of neovascularization was scored.
RESULTS: The inner nuclear layer of oxygen-exposed retinas exhibited a continuous intense band of VPF/VEGF messenger RNA expression across the peripheral avascular zone that dropped sharply in vascular retina. Neovascularization occurred adjacent to regions of greatest expression. Controls had much lower expression and smaller avascular regions. The VPF/VEGF messenger RNA expression was most intense in Müller cells, scattered astrocytes, and amacrine cells, strong in retinal pigment epithelium, and moderate in the remaining inner nuclear layer and ganglion cell layer.
CONCLUSION: The expression of VPF/VEGF message was spatially and quantitatively correlated with the neovascularization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8859080     DOI: 10.1001/archopht.1996.01100140410008

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  24 in total

1.  Diode laser treatment of posterior retinopathy of prematurity.

Authors:  R Axer-Siegel; M Snir; D Cotlear; A Maayan; R Frilling; I Rosenbaltt; D Weinberger; I Kremer; L Sirota
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 2.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

3.  Imaging oxygen pressure in the rodent retina by phosphorescence lifetime.

Authors:  David F Wilson; Sergei A Vinogradov; Pavel Grosul; Newman Sund; M Noel Vacarezza; Jean Bennett
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

Review 4.  The neurovascular retina in retinopathy of prematurity.

Authors:  Anne B Fulton; Ronald M Hansen; Anne Moskowitz; James D Akula
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

5.  Oxygen distribution and vascular injury in the mouse eye measured by phosphorescence-lifetime imaging.

Authors:  David F Wilson; Sergei A Vinogradov; Pavel Grosul; M Noel Vaccarezza; Akiko Kuroki; Jean Bennett
Journal:  Appl Opt       Date:  2005-09-01       Impact factor: 1.980

Review 6.  Vascular endothelial growth factor and ocular neovascularization.

Authors:  J W Miller
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

7.  Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor.

Authors:  V Stellmach; S E Crawford; W Zhou; N Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

8.  A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.

Authors:  Manas R Biswal; Howard M Prentice; C Kathleen Dorey; Janet C Blanks
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-06       Impact factor: 4.799

9.  Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model.

Authors:  Yuta Saito; Abhineet Uppal; Grace Byfield; Steven Budd; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

10.  Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity.

Authors:  Yuta Saito; Pete Geisen; Abhineet Uppal; M Elizabeth Hartnett
Journal:  Mol Vis       Date:  2007-06-12       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.